---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-103707"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:22:07.969924+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences enters ATM equity facility for up to $1.75M through Lucid Capital Markets

## Summary
- Aggregate gross proceeds up to $1,750,000 from sale of common stock at-the-market.
- Lucid Capital Markets acts as sales agent with a 3.0% commission on gross proceeds.
- Sales may be made directly on Nasdaq Capital Market or in negotiated transactions.
- Agreement effective October 29, 2025; terminates upon full sale, earlier termination, or 3-year anniversary.
- Company has no obligation to sell any shares and may suspend or terminate at any time.

## SEC filing metadata
- accession: 0001213900-25-103707
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000121390025103707/0001213900-25-103707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000121390025103707/ea0263059-8k_endra.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-103707
- JSON: https://secwatch.observer/filing/0001213900-25-103707.json
- Plain text: https://secwatch.observer/filing/0001213900-25-103707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.